https://doi.org/10.48047/AFJBS.6.Si1.2024.188-197

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Antimicrobial Peptides: Potential Therapeutic Agents for Infectious Diseases

Dr.Mrs. Priyanka M.Mane, Assistant Professor
Dept. of Microbiology Krishna Institute of Medical Sciences
Krishna Vishwa Vidyapeeth "Deemed to be University",Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India
mane.priyanka1984@ gmail.com

Dr. Mrs. G.S. Karande, Professor
Dept. of Microbiology Krishna Institute of Medical Sciences
Krishna Vishwa Vidyapeeth "Deemed to be University",Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India
gskarande68@gmail.com

Dr. R.V. Shinde, Associate Professor
Dept. of Microbiology Krishna Institute of Medical Sciences
Krishna Vishwa Vidyapeeth "Deemed to be University",Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India
dr.ravi910@gmail.com

Elham Mohammed Khatrawi
Department of Basic Medical Sciences, College of Medicine , Taibah University Madinah 42353, Saudi Arabia
ekhatrawi@taibahu.edu.sa
ORCID 0000-0003-1340-4437

Article History

Volume 6,Issue Si1, 2024

Received:19 Mar 2024

Accepted : 30 Apr 2024

doi:10.48047/AFJBS.6.Si1.2024.188-197

Abstract

Antimicrobial peptides (AMPs) have emerged as potent therapeutic agents against a wide range of infectious diseases, offering a promising alternative to traditional antibiotics in the face of rising antimicrobial resistance. AMPs, which are integral components of the innate immune system, exhibit broad-spectrum activity against bacteria, viruses, fungi, and parasites through mechanisms distinct from those of conventional antibiotics. This review explores the history and discovery of AMPs, elucidates their mechanisms of action, and classifies them based on their sources, structures, and functions. The therapeutic applications of AMPs are highlighted, showcasing their efficacy in treating various infections, including those caused by multidrug-resistant pathogens. The advantages of AMPs, such as their rapid action, low propensity for resistance development, immunomodulatory properties, and synergistic effects with other antimicrobials, are discussed in detail. However, challenges such as stability, potential toxicity, delivery methods, and production costs are identified as obstacles that need to be addressed. Current clinical trials and research advancements are reviewed, emphasizing the ongoing efforts to overcome these limitations. Finally, future directions and innovations in AMP research, including novel design strategies, advanced delivery systems, and personalized medicine approaches, are considered. This comprehensive review underscores the potential of AMPs to revolutionize the treatment of infectious diseases and highlights the necessity for continued research and development in this field.

Introduction

Antimicrobial peptides (AMPs) have emerged as promising candidates in the battle against infectious diseases, which continue to pose significant global health challenges. The rise of antibiotic resistance, coupled with the emergence of new and re-emerging infectious agents, has driven the search for novel therapeutic approaches. AMPs, also known as host defense peptides, are a diverse group of molecules that play a crucial role in the innate immune system of many organisms, from bacteria to humans [1].

AMPs are characterized by their ability to kill a wide range of pathogens, including bacteria, viruses, fungi, and parasites, through mechanisms that are distinct from those of traditional antibiotics. This broad-spectrum activity and the relatively low propensity for resistance development make AMPs attractive as potential therapeutic agents. Moreover, AMPs often exhibit additional immunomodulatory properties, enhancing the host's immune response and providing a multifaceted approach to combating infections [2].

The urgency to develop new antimicrobial agents cannot be overstated. According to the World Health Organization (WHO), antimicrobial resistance is one of the top ten global public health threats facing humanity. The overuse and misuse of antibiotics in humans and animals have accelerated the emergence of resistant strains, rendering many existing treatments ineffective. This has led to increased morbidity, mortality, and healthcare costs, highlighting the need for innovative solutions like AMPs [3].

In this article, we will explore the potential of AMPs as therapeutic agents for infectious diseases. We will delve into their history and discovery, mechanisms of action, classification, and therapeutic applications. Additionally, we will discuss the advantages of AMPs over traditional antibiotics, the challenges and limitations in their development, and the current state of clinical trials and research. Finally, we will consider future directions and innovations in the field of AMPs, underscoring their promise as a key component of next-generation antimicrobial therapies.

The journey of AMPs from their initial discovery to their current status as potential therapeutic agents is marked by significant scientific advancements and a growing understanding of their multifunctional roles. As we navigate through this comprehensive review, it becomes evident that AMPs hold the potential to revolutionize the treatment of infectious diseases, offering hope in an era of escalating antimicrobial resistance.

History and Discovery of Antimicrobial Peptides

The discovery of antimicrobial peptides dates back several decades, with roots in the observation of natural antimicrobial substances in various organisms. The concept of innate immunity, where organisms possess inherent defense mechanisms against pathogens, laid the foundation for the identification of AMPs. One of the earliest discoveries was lysozyme, an enzyme with antibacterial properties found in egg whites and human tears, discovered by Alexander Fleming in 1922 [4].

However, the modern era of AMP research began in the 1980s with the identification of cecropins in insects and magainins in amphibians. These discoveries highlighted the existence of potent antimicrobial molecules in organisms as diverse as insects and frogs, sparking interest in the broader search for similar peptides across the animal kingdom.

Cecropins, isolated from the hemolymph of the moth Hyalophora cecropia, demonstrated broad-spectrum antibacterial activity and provided a model for studying the structure and function of AMPs [5].

In parallel, the discovery of defensins in mammals, including humans, underscored the evolutionary conservation of AMPs and their critical role in host defense. Defensins are small, cysteine-rich peptides found in various tissues, including the skin, respiratory tract, and gastrointestinal tract, where they serve as a first line of defense against invading pathogens [6]. The identification of these peptides in humans opened new avenues for exploring their therapeutic potential.

The 1990s and early 2000s saw a surge in the identification and characterization of AMPs from diverse sources, including plants, marine organisms, and microorganisms. These discoveries expanded the repertoire of known AMPs and provided insights into their structural diversity and mechanisms of action. For example, cathelicidins, a family of AMPs found in humans and other mammals, were shown to possess not only antimicrobial activity but also immunomodulatory functions, enhancing their appeal as therapeutic agents [7].

As research progressed, the application of advanced techniques in genomics, proteomics, and bioinformatics facilitated the discovery of new AMPs and the optimization of existing ones. High-throughput screening methods and computational modeling allowed for the identification of AMPs with enhanced activity and stability, addressing some of the challenges associated with their therapeutic use [8].

The historical journey of AMPs from natural observations to sophisticated scientific exploration reflects the growing recognition of their potential in combating infectious diseases. The continued study of AMPs promises to unlock new therapeutic strategies, offering hope in the fight against antibiotic-resistant pathogens and emerging infections.

Mechanisms of Action

The mechanisms by which antimicrobial peptides exert their effects on pathogens are diverse and complex, reflecting their evolutionary adaptation to combat a wide range of microorganisms. Unlike traditional antibiotics, which often target specific bacterial functions or structures, AMPs typically disrupt the integrity of microbial cell membranes, leading to rapid cell death [9].

One of the primary mechanisms of action of AMPs involves the interaction with microbial cell membranes. Most AMPs are positively charged, allowing them to bind to the negatively charged components of microbial membranes, such as phospholipids and lipopolysaccharides. This electrostatic attraction facilitates the insertion of AMPs into the membrane, where they can form pores or disrupt the lipid bilayer, leading to leakage of cellular contents and cell lysis [10].

For example, the α-helical AMP magainin, derived from frog skin, forms transmembrane pores by inserting into the lipid bilayer and aggregating to create ion channels. This pore formation disrupts the membrane potential and integrity, ultimately causing cell death. Similarly, β-sheet AMPs, such as defensins, can insert into membranes and form pore-like structures, leading to rapid microbial killing [11].

In addition to membrane disruption, some AMPs can interfere with intracellular targets once they penetrate the microbial cell. For instance, certain AMPs can inhibit protein synthesis, nucleic acid synthesis, or enzymatic activity, further compromising the viability of the pathogen. These multifaceted mechanisms reduce the likelihood of resistance development, as the pathogen would need to simultaneously acquire multiple mutations to evade the AMP's effects [12].

AMPs also exhibit immunomodulatory properties that enhance their antimicrobial activity. They can recruit and activate immune cells, such as macrophages and neutrophils, to the site of infection, promoting phagocytosis and clearance of pathogens. Furthermore, AMPs can modulate the production of cytokines and chemokines, shaping the immune response to infection. For example, the human AMP LL-37 has been shown to promote wound healing and modulate inflammation, highlighting its dual role in host defense and immune regulation [13].

The ability of AMPs to act on multiple fronts—disrupting membranes, targeting intracellular components, and modulating the immune response—underscores their potential as broad-spectrum antimicrobial agents. This multifaceted mode of action not only enhances their efficacy but also mitigates the risk of resistance development, a significant advantage over conventional antibiotics.

Classification and Types of AMPs

Antimicrobial peptides are classified based on their source, structure, and function, reflecting their diversity and specialized roles in host defense. This classification helps in understanding their mechanisms of action and potential therapeutic applications.

1. **Source-Based Classification**: AMPs can be derived from various natural sources, including animals, plants, and microorganisms. Animal-derived AMPs, such as defensins and cathelicidins, are found in mammals, birds, and insects. Plant-derived AMPs, like thionins and defensins, play a crucial role in protecting plants against microbial pathogens. Microorganism-derived AMPs, such as bacteriocins, are produced by bacteria and fungi as part of their competitive survival strategies [14].
2. **Structure-Based Classification**: AMPs are also classified based on their structural features. The primary structures of AMPs can vary significantly, but they generally fall into four major categories:
    - **α-Helical Peptides**: These peptides, such as magainins and cecropins, adopt an α-helical structure in membrane environments. Their helical nature allows them to insert into microbial membranes and form pores, disrupting membrane integrity.
    - **β-Sheet Peptides**: Peptides like defensins contain β-sheet structures stabilized by disulfide bonds. These structures facilitate the formation of pore-like channels in microbial membranes.
    - **Extended Peptides**: These AMPs lack a defined secondary structure and are rich in specific amino acids, such as proline and arginine. Examples include indolicidin and histatins.
    - **Loop Peptides**: Characterized by one or more loop structures stabilized by disulfide bonds, these peptides include theta-defensins found in primates [15].
3. **Function-Based Classification**: AMPs can also be categorized based on their primary biological functions:

- **Antibacterial Peptides**: These AMPs target bacterial pathogens and include well-known examples like human defensins and cathelicidins.
- **Antiviral Peptides**: AMPs with activity against viruses, such as LL-37, which can inhibit viral entry and replication.
- **Antifungal Peptides**: These peptides, such as histatins, target fungal pathogens by disrupting their cell membranes and inhibiting growth.
- **Antiparasitic Peptides**: AMPs that target parasites, including protozoa and helminths, by various mechanisms, including membrane disruption and interference with metabolism [16].

Understanding the classification of AMPs provides insight into their diverse mechanisms and potential therapeutic applications. Each class of AMP offers unique advantages, and their combined use may enhance the efficacy of antimicrobial therapies.

Therapeutic Applications in Infectious Diseases

The therapeutic potential of antimicrobial peptides extends across a wide spectrum of infectious diseases, offering novel solutions where traditional antibiotics may fall short. Their ability to target diverse pathogens and modulate the immune response makes them versatile agents in the treatment of bacterial, viral, fungal, and parasitic infections.

1. **Bacterial Infections**: AMPs have shown promise in treating bacterial infections, particularly those caused by antibiotic-resistant strains. For example, the human AMP LL-37 has demonstrated activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, two common multidrug-resistant pathogens. Additionally, AMPs like colistin and polymyxin B are already used clinically to treat severe infections caused by Gram-negative bacteria [17].
2. **Viral Infections**: AMPs also exhibit antiviral properties, making them potential candidates for treating viral infections. Peptides like LL-37 and defensins have been shown to inhibit the replication of enveloped viruses, such as influenza and HIV, by disrupting viral membranes and interfering with viral entry into host cells. Their immunomodulatory effects further enhance the antiviral response, offering a multifaceted approach to therapy [18].
3. **Fungal Infections**: The rise of fungal infections, particularly in immunocompromised individuals, has highlighted the need for new antifungal agents. AMPs like histatins and defensins exhibit potent antifungal activity by disrupting fungal cell membranes and inhibiting biofilm formation. These properties make them valuable in treating infections caused by Candida species and other pathogenic fungi [19].
4. **Parasitic Infections**: AMPs have shown efficacy against parasitic infections, including those caused by protozoa and helminths. For instance, the AMPdermaseptin, derived from frog skin, has demonstrated activity against the malaria parasite Plasmodium falciparum. Similarly, defensins have been shown to inhibit the growth of Leishmania species, highlighting their potential in treating parasitic diseases [20].

The broad-spectrum activity of AMPs, combined with their ability to modulate the immune response, positions them as versatile therapeutic agents. Their use in combination with traditional antibiotics or as standalone treatments offers a promising strategy to combat infectious diseases in the era of increasing antibiotic resistance.

Advantages over Traditional Antibiotics

Antimicrobial peptides (AMPs) offer several advantages over traditional antibiotics, making them attractive candidates for next-generation antimicrobial therapies. These advantages stem from their unique mechanisms of action, broad-spectrum activity, and immunomodulatory properties. [1-8,12-15]

1. **Broad-Spectrum Activity**: Unlike traditional antibiotics, which often target specific bacterial functions, AMPs can act against a wide range of pathogens, including bacteria, viruses, fungi, and parasites. This broad-spectrum activity makes them versatile agents capable of treating various infections with a single therapeutic approach. For instance, AMPs like LL-37 and defensins have shown efficacy against both Gram-positive and Gram-negative bacteria, as well as fungi and viruses.
2. **Low Propensity for Resistance Development**: The rapid killing mechanism of AMPs, primarily through membrane disruption, reduces the likelihood of resistance development. Pathogens would need to undergo multiple genetic mutations to evade the effects of AMPs, making it more difficult for resistance to emerge. This contrasts with traditional antibiotics, where resistance can develop through specific mutations or acquisition of resistance genes. For example, magainin and other AMPs have demonstrated sustained effectiveness against bacterial strains that have developed resistance to conventional antibiotics.
3. **Rapid Action**: AMPs typically kill pathogens quickly, often within minutes of contact. This rapid action is crucial in preventing the spread of infection and reducing the overall pathogen load. The fast-acting nature of AMPs can be particularly beneficial in treating acute infections and sepsis, where timely intervention is critical. For example, the AMP melittin, derived from bee venom, has shown rapid bactericidal activity against a variety of pathogens.
4. **Immunomodulatory Properties**: In addition to their direct antimicrobial activity, many AMPs can modulate the host immune response. They can enhance the recruitment and activation of immune cells, promote wound healing, and reduce inflammation. These immunomodulatory effects provide a dual mechanism of action, enhancing the overall effectiveness of the therapy. LL-37, for instance, not only exhibits broad-spectrum antimicrobial activity but also modulates immune responses by promoting the chemotaxis of immune cells and enhancing the production of cytokines.
5. **Synergistic Effects with Other Antimicrobials**: AMPs can act synergistically with traditional antibiotics, enhancing their efficacy and reducing the required dosage. This synergistic interaction can help overcome antibiotic resistance and improve treatment outcomes. For example, combining AMPs with antibiotics like vancomycin has shown increased effectiveness against resistant bacterial strains. Studies have demonstrated that combining the AMP colistin with other antibiotics significantly enhances their antimicrobial activity against multidrug-resistant bacteria.
6. **Reduced Side Effects**: Traditional antibiotics can cause significant side effects, including gastrointestinal disturbances, allergic reactions, and disruptions to the normal microbiota. AMPs, due to their targeted mechanisms of action and rapid degradation in the body, often exhibit fewer side effects and reduced toxicity. This makes them safer alternatives, particularly for patients with compromised health or those requiring long-term antimicrobial therapy.
7. **Potential for Targeted Therapies**: Advances in AMP design and delivery systems have opened the door for targeted therapies. By modifying AMPs to target specific

pathogens or using delivery vehicles such as nanoparticles and liposomes, it is possible to enhance their specificity and reduce off-target effects. This targeted approach can increase the efficacy of AMPs while minimizing potential harm to host tissues.

The combined advantages of broad-spectrum activity, low resistance potential, rapid action, immunomodulatory properties, synergistic effects, reduced side effects, and potential for targeted therapies make AMPs promising candidates for addressing the limitations of traditional antibiotics. Their unique attributes offer hope for developing effective therapies in the fight against infectious diseases, particularly in an era where antibiotic resistance is a growing concern.

Challenges and Limitations

Despite their promising potential, the development and clinical use of antimicrobial peptides face several challenges and limitations that need to be addressed to realize their full therapeutic potential. [11-16]

1. **Stability and Degradation**: One of the primary challenges in AMP development is their stability. AMPs are prone to degradation by proteolytic enzymes in the body, which can reduce their effectiveness. Enhancing the stability of AMPs through chemical modifications, such as cyclization or incorporation of non-natural amino acids, is an area of active research.
2. **Potential Toxicity and Side Effects**: While AMPs are generally considered safe, some peptides can exhibit toxicity toward host cells at higher concentrations. Balancing antimicrobial efficacy with host cell selectivity is critical to minimize potential side effects. Understanding the structure-activity relationship of AMPs can aid in designing peptides with reduced toxicity.
3. **Delivery Methods and Formulation Challenges**: Effective delivery of AMPs to the site of infection is crucial for their therapeutic success. AMPs can be administered topically, orally, or through injection, but each route has its challenges. For instance, oral delivery faces obstacles such as degradation in the gastrointestinal tract and poor bioavailability. Developing novel delivery systems, such as nanoparticles orliposomes, can enhance the stability and targeting of AMPs.
4. **Cost of Production**: The cost of synthesizing AMPs can be higher than that of traditional antibiotics, posing economic challenges for large-scale production and commercialization. Advances in peptide synthesis technologies and recombinant expression systems may help reduce production costs and make AMPs more accessible for clinical use.
5. **Regulatory and Clinical Trial Hurdles**: The path to regulatory approval for new antimicrobial agents can be lengthy and complex. Ensuring the safety, efficacy, and consistency of AMPs through rigorous preclinical and clinical testing is essential. Overcoming these regulatory hurdles requires collaboration between researchers, industry, and regulatory bodies to streamline the development process.

Addressing these challenges is crucial for the successful translation of AMPs from the laboratory to the clinic. Continued research and innovation in peptide design, delivery systems, and production methods will be key to overcoming these obstacles and harnessing the therapeutic potential of AMPs.

Current Clinical Trials and Research

The clinical development of antimicrobial peptides has gained momentum in recent years, with several AMPs advancing through various stages of clinical trials. These trials aim to evaluate the safety, efficacy, and potential applications of AMPs in treating infectious diseases.

1. **Ongoing Clinical Trials**: Numerous AMPs are currently undergoing clinical trials for various indications. For instance, pexiganan, a synthetic analog of magainin, has been investigated for the treatment of diabetic foot ulcers, demonstrating promising results in reducing infection and promoting wound healing. Similarly, the AMP LL-37 has been evaluated for its potential to treat chronic skin infections and enhance tissue repair.
2. **Recent Breakthroughs**: Recent research has highlighted the potential of AMPs in combination therapies. For example, combining AMPs with conventional antibiotics has shown synergistic effects, enhancing the overall antimicrobial activity and reducing the likelihood of resistance development. Studies have also explored the use of AMPs in novel delivery systems, such as encapsulation in nanoparticles, to improve their stability and targeting.
3. **Experimental Studies**: Experimental studies continue to expand our understanding of AMP mechanisms and optimize their therapeutic potential. Research efforts are focused on designing AMPs with enhanced activity, stability, and specificity. Techniques such as peptide engineering, structure-activity relationship studies, and high-throughput screening are being employed to discover and develop next-generation AMPs with improved properties.

Future Directions and Innovations

The future of antimicrobial peptides holds great promise, with ongoing research and development aimed at overcoming current limitations and enhancing their therapeutic potential. Several key areas of innovation are poised to drive the advancement of AMPs as effective treatments for infectious diseases.

1. **Advances in AMP Design**: The design of novel AMPs with improved stability, efficacy, and selectivity is a major focus. Using techniques such as rational design, peptide library screening, and bioinformatics, researchers are developing AMPs with optimized properties. Incorporating non-natural amino acids, cyclization, and peptide mimetics are strategies being explored to enhance stability and activity.
2. **Novel Delivery Systems**: The development of innovative delivery systems can address challenges related to AMP stability and targeting. Nanotechnology-based approaches, such as nanoparticles, liposomes, and hydrogels, offer promising solutions for delivering AMPs effectively to the site of infection. These systems can protect AMPs from degradation, enhance their bioavailability, and provide sustained release.
3. **Personalized Medicine**: The integration of AMPs into personalized medicine approaches holds potential for tailored therapies. By leveraging advances in genomics and proteomics, it is possible to design AMPs that target specific pathogens or patient-specific factors. Personalized AMP therapies can enhance treatment outcomes and reduce the risk of resistance development.

4. **Combination Therapies**: Exploring the synergistic potential of AMPs in combination with other antimicrobial agents is a promising avenue. Combining AMPs with traditional antibiotics, immune modulators, or other therapeutic peptides can enhance their efficacy and broaden their spectrum of activity. These combination therapies can provide multifaceted approaches to combating infections.
5. **Regulatory Pathways**: Streamlining regulatory pathways for AMP approval is crucial for their successful clinical translation. Collaborative efforts between researchers, industry, and regulatory agencies can facilitate the development of standardized protocols, safety assessments, and efficacy evaluations. Establishing clear guidelines and frameworks will accelerate the regulatory approval process and promote the clinical use of AMPs.

Conclusion

Antimicrobial peptides represent a promising class of therapeutic agents with the potential to revolutionize the treatment of infectious diseases. Their unique mechanisms of action, broad-spectrum activity, immunomodulatory properties, and low propensity for resistance development position them as valuable alternatives to traditional antibiotics. Despite challenges related to stability, toxicity, delivery, and cost, ongoing research and innovation are addressing these limitations and driving the advancement of AMPs.

The future of AMPs lies in the development of novel designs, innovative delivery systems, personalized medicine approaches, and combination therapies. Continued collaboration and investment in research will be essential to unlock the full potential of AMPs and bring them to the forefront of antimicrobial therapy. With their multifaceted capabilities, AMPs offer hope in the fight against antibiotic resistance and emerging infectious diseases, providing a new frontier in the battle for global health.

By harnessing the power of antimicrobial peptides, we can pave the way for a new era of effective, targeted, and sustainable treatments for infectious diseases, ultimately improving patient outcomes and safeguarding public health.

References

1. Ganz, T. (2003). Defensins: Antimicrobial peptides of innate immunity. *Nature Reviews Immunology, 3*(9), 710-720. https://doi.org/10.1038/nri1180
2. Hancock, R. E., & Sahl, H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nature Biotechnology, 24*(12), 1551-1557. https://doi.org/10.1038/nbt1267
3. World Health Organization. (2019). No time to wait: Securing the future from drug-resistant infections. Retrieved from https://www.who.int/publications-detail-redirect/no-time-to-wait-securing-the-future-from-drug-resistant-infections
4. Fleming, A. (1922). On a remarkable bacteriolytic element found in tissues and secretions. *Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character, 93*(653), 306-317. https://doi.org/10.1098/rspb.1922.0023
5. Steiner, H., Hultmark, D., Engström, A., Bennich, H., & Boman, H. G. (1981). Sequence and specificity of two antibacterial proteins involved in insect immunity. *Nature, 292*(5820), 246-248. https://doi.org/10.1038/292246a0

6. Lehrer, R. I., & Ganz, T. (1999). Antimicrobial peptides in mammalian and insect host defence. *Current Opinion in Immunology, 11*(1), 23-27. https://doi.org/10.1016/S0952-7915(99)80004-6
7. Zaiou, M., & Gallo, R. L. (2002). Cathelicidins, essential gene-encoded mammalian antibiotics. *Journal of Molecular Medicine, 80*(9), 549-561. https://doi.org/10.1007/s00109-002-0350-9
8. Wang, G. (2015). Improved methods for classification, prediction, and design of antimicrobial peptides. *Methods in Molecular Biology, 1268*, 43-66. https://doi.org/10.1007/978-1-4939-2285-7_3
9. Brogden, K. A. (2005). Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? *Nature Reviews Microbiology, 3*(3), 238-250. https://doi.org/10.1038/nrmicro1098
10. Yeaman, M. R., & Yount, N. Y. (2003). Mechanisms of antimicrobial peptide action and resistance. *Pharmacological Reviews, 55*(1), 27-55. https://doi.org/10.1124/pr.55.1.2
11. Zasloff, M. (2002). Antimicrobial peptides of multicellular organisms. *Nature, 415*(6870), 389-395. https://doi.org/10.1038/415389a
12. Hancock, R. E. W., & Chapple, D. S. (1999). Peptide antibiotics. *Antimicrobial Agents and Chemotherapy, 43*(6), 1317-1323. https://doi.org/10.1128/AAC.43.6.1317
13. Niyonsaba, F., & Ogawa, H. (2005). Protective roles of the skin against infection: Implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. *Journal of Dermatological Science, 40*(3), 157-168. https://doi.org/10.1016/j.jdermsci.2005.04.002
14. Bulet, P., Stocklin, R., & Menin, L. (2004). Anti-microbial peptides: From invertebrates to vertebrates. *Immunological Reviews, 198*(1), 169-184. https://doi.org/10.1111/j.0105-2896.2004.0119.x
15. Hoskin, D. W., & Ramamoorthy, A. (2008). Studies on anticancer activities of antimicrobial peptides. *Biochimica et Biophysica Acta (BBA) - Biomembranes, 1778*(2), 357-375. https://doi.org/10.1016/j.bbamem.2007.11.008
16. Reddy, K. V. R., Yedery, R. D., & Aranha, C. (2004). Antimicrobial peptides: Premises and promises. *International Journal of Antimicrobial Agents, 24*(6), 536-547. https://doi.org/10.1016/j.ijantimicag.2004.09.005
17. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., Foster, S., Gilmore, B. F., Hancock, R. E., Harper, D., Henderson, I. R., Hilpert, K., Jones, B. V., Kadioglu, A., Knowles, D., Ólafsdóttir, S., Payne, D., Projan, S., Shaunak, S., ... & Rex, J. H. (2016). Alternatives to antibiotics-a pipeline portfolio review. The Lancet Infectious Diseases, 16(2), 239-251. https://doi.org/10.1016/S1473-3099(15)00466-1
18. de la Fuente-Núñez, C., Silva, O. N., Lu, T. K., & Franco, O. L. (2017). Antimicrobial peptides: Role in human disease and potential as immunotherapies. Pharmacology & Therapeutics, 178, 132-140. https://doi.org/10.1016/j.pharmthera.2017.04.002
19. Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016). Antimicrobial peptides: An emerging category of therapeutic agents. Frontiers in Cellular and Infection Microbiology, 6, 194. https://doi.org/10.3389/fcimb.2016.00194
20. Pletzer, D., & Hancock, R. E. W. (2016). Antibiofilm peptides: Potential as broad-spectrum agents. Journal of Bacteriology, 198(19), 2572-2578. https://doi.org/10.1128/JB.00017-16